Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

disease   published : Today    save search

Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight
Published: 2024-04-24 (Crawled : 22:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
OTLK | News P | $8.2 0.0% 240K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
KOD | News | $3.37 1.2% 1.19% 340K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
OPT | News | $3.46 2.98% 2.89% 8.2K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

disease market
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FRLN | $6.48 0.0% 0 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

disease cell meeting parkinson’s therapy
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K twitter stocktwits trandingview |
Health Technology
| | O: -0.17% H: 0.08% C: -1.9%

disease kidney treatment pharmaceuticals for study
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: -0.29% H: 0.0% C: 0.0%

gt-0228 disease positive for parkinson’s trial therapeutics therapy results
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K twitter stocktwits trandingview |
Manufacturing
| | O: 5.72% H: 3.18% C: -3.82%

first disease biopharma for
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services

BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services

MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services

WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services

AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services

MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information

RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance


Your saved searches
Save your searches and get alerts when important news are released.